Why Farbe Firma is the Top Manufacturer of Aprotinin Injection
- Maulik Sudani
- 1 day ago
- 8 min read
Last Updated: June 22, 2026
TL;DR: Aprotinin Injection — a sterile, clear, colourless aqueous solution of aprotinin, a naturally derived bovine polypeptide that acts as a broad-spectrum serine protease inhibitor with antifibrinolytic activity, inhibiting trypsin, plasmin and plasma and tissue kallikrein, supplied commonly as a 10,000 KIU/mL solution given by slow intravenous injection and infusion after a mandatory test dose — is a specialist hospital medicine used to reduce perioperative blood loss and the need for blood transfusion in selected patients undergoing isolated coronary artery bypass graft surgery with cardiopulmonary bypass. Because aprotinin is a heat-labile protein whose potency is measured biologically in kallikrein inactivator units, is sourced from bovine tissue, and carries a real risk of anaphylactic reactions on re-exposure, each unit must deliver an exact, sterile, particulate-free dose at the labelled potency, with the potency bioassay, the protein and related-protein profile, source and viral/TSE safety, bioburden and endotoxin control, an aseptic-only fill, cold-chain handling, low particulate and verified container-closure integrity all mattering to safety and shelf life. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Aprotinin Injection at our Gujarat, India facility and supplies it to cardiac-surgery, anaesthesia, perfusion and hospital-pharmacy services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Broad-spectrum serine protease inhibitor and antifibrinolytic — aprotinin is a bovine-derived polypeptide that inhibits trypsin, plasmin and plasma and tissue kallikrein, and Aprotinin Injection (10,000 KIU/mL, slow intravenous after a test dose) reduces perioperative blood loss and transfusion need in isolated coronary artery bypass graft surgery with cardiopulmonary bypass, where an exact, sterile, reproducible biologic dose is critical.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core (aseptic-only fill for a heat-labile protein), validated water-for-injection loops, dedicated compounding and vial filling lines, control of the potency (KIU) bioassay, the protein and related-protein profile, bioburden, solution pH, fill volume, particulate and endotoxin, with container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, validated cold-chain (2–8 °C) stability data, potency bioassay and protein-characterisation method-validation data, bovine-source viral/TSE safety documentation, sterilisation and container-closure data, drug master files and CEP-style documentation for ministry-of-health, hospital-formulary and institutional tenders.
End-to-end CDMO services: Sterile biologic-solution vial contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, cold-chain-ready tamper-evident tender packaging and import/export coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Aprotinin Injection Demands a Premium Manufacturer
Aprotinin Injection holds a critical, specialised place in cardiac-surgery theatres, perfusion suites and anaesthesia services. It is the antifibrinolytic that cardiac teams reach for to reduce perioperative blood loss and the need for donor-blood transfusion in selected patients undergoing isolated coronary artery bypass graft surgery on cardiopulmonary bypass — where contact of the patient's blood with the artificial surfaces of the bypass circuit activates fibrinolysis, the contact-coagulation pathway and a systemic inflammatory response. What makes aprotinin distinctive is that it is not a small synthetic molecule but a naturally derived bovine polypeptide, a broad-spectrum serine protease inhibitor that blocks trypsin, plasmin and plasma and tissue kallikrein, and whose strength is expressed not as milligrams of a pure chemical but in kallikrein inactivator units (KIU) of biological activity. Because the product is used in major surgery in patients at risk of significant bleeding, the dose delivered from each unit must be exact, sterile, particulate-free and reliably the same in potency from unit to unit, since the surgical and perfusion team depend on a precise, ready, reproducible biologic dose.
That clinical reality places exceptional demands on the manufacturer. Aprotinin Injection is a protein solution — commonly 10,000 KIU/mL — so potency must be confirmed by a validated biological assay rather than a simple chemical percentage, and the fill volume must be accurate so each unit delivers the labelled units of activity. Above all, aprotinin is a heat-labile polypeptide: it cannot be terminally sterilised by autoclaving without destroying the protein, so the product must be made by full aseptic processing with sterile filtration and rigorous bioburden and endotoxin control, and it is typically stored refrigerated and protected from extremes of temperature to preserve activity. Because it is sourced from bovine tissue, the manufacturer must control source-animal qualification and viral and TSE (transmissible spongiform encephalopathy) safety with validated removal/inactivation and full traceability; because re-exposure to aprotinin can provoke anaphylaxis, the label must carry the mandatory test-dose, antihistamine-prophylaxis and re-exposure warnings; and the solution must be free of visible and sub-visible particulates and protein aggregates and low in endotoxin. Choosing an Aprotinin Injection manufacturer that treats the potency bioassay, protein and related-protein characterisation, bovine-source viral/TSE safety, aseptic-only sterility assurance, cold-chain stability, fill-volume accuracy, particulate and endotoxin control and container-closure integrity as core engineering disciplines is what protects the patient at the point of care.
What Sets a World-Class Aprotinin Injection Manufacturer Apart
A world-class manufacturer of Aprotinin Injection invests in three areas that weaker suppliers underfund: a precise, validated potency bioassay in kallikrein inactivator units with protein-content and related-protein/aggregate characterisation that a biologic antifibrinolytic demands, a robust, validated, aseptic-only sterilisation and fill process — backed by cold-chain stability data and rigorous bioburden, endotoxin and bovine-source viral/TSE safety control — that protects sterility, potency and clarity in a heat-labile protein that cannot be terminally autoclaved, and tender-ready dossier support for a high-risk specialist hospital biologic procured through cardiac-surgery, pharmacy and ministry-of-health channels. It starts with the active — pharmacopoeial-grade aprotinin sourced from qualified, audited suppliers with documented bovine-source control, with full potency, protein, related-protein and impurity profiling and certificates of analysis verified by the receiving laboratory before the material enters production.
Compounding and filling then have to defend the potency, the clarity, the pH and the sterility of a protein solution that cannot see terminal heat. The bulk solution is compounded in water-for-injection at the controlled pH that keeps aprotinin stable, then sterile-filtered through 0.22 µm membrane and filled into vials under ISO Class 5 conditions with strict bioburden control before filtration and a fully validated aseptic process — there is no terminal autoclave step for this heat-labile polypeptide, so sterility assurance rests on the validated aseptic fill, media fills and environmental monitoring. Filled units are 100 % inspected for fill, seal, clarity and particulate or aggregate defects; in-process and release testing confirm the potency of aprotinin by validated KIU bioassay, the protein content and related-protein/aggregate profile, solution pH, deliverable (fill) volume, visible and sub-visible particulate matter, and that endotoxin is held well within limits so the solution is safe for intravenous administration. Because aprotinin is a heat-labile, bovine-derived biologic, potency assurance, protein characterisation, viral/TSE safety, aseptic sterility assurance, cold-chain stability and container-closure integrity are validated together so the potency, clarity and safety stay within specification across shelf life.
Quality Systems Behind Every Aprotinin Injection
Every Farbe Firma Aprotinin Injection batch is released only after a full stack of quality checks: validated potency bioassay of aprotinin in kallikrein inactivator units against reference standards, protein content and related-protein/aggregate profile by validated methods, solution pH, clarity and colour of the solution, deliverable (fill) volume, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, and container-closure integrity for the vial format, with documented bovine-source viral/TSE safety. Certificates of analysis are issued with full traceability back to each API lot, the documented source material, the primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, validated aseptic filling lines with media fills and 100 % inspection, cold-chain handling and monitoring, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because aprotinin injection is a heat-labile, bovine-derived biologic antifibrinolytic and the potency, protein profile, viral/TSE safety, sterility, particulate and endotoxin burden drive both efficacy and safety, we treat the potency bioassay, the protein and related-protein/aggregate profile, the sterility assurance, the solution pH and the deliverable volume as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under long-term and accelerated ICH Q1A conditions and under refrigerated (2–8 °C) cold-chain conditions, so the potency, clarity and safety stay within specification across the labelled shelf life.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Aprotinin Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables, including a specialised cardiac-surgery, anaesthesia and critical-care small-volume parenteral and biologic portfolio. For Aprotinin Injection specifically, we supply the 10,000 KIU/mL solution in vial presentations under WHO-GMP conditions, with country-specific potencies, fill configurations, cold-chain-ready tamper-evident packs and pack counts available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier — including the potency-bioassay, protein-characterisation, bovine-source viral/TSE safety, cold-chain stability, aseptic-sterility and container-closure data package — ready to hand for registration and tender qualification.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A and validated cold-chain stability packages, potency-bioassay and protein-characterisation method-validation data, bovine-source viral/TSE safety documentation, aseptic-sterility and container-closure reports, translated package inserts and artwork — including the mandatory test-dose, antihistamine-prophylaxis, re-exposure-anaphylaxis and cold-chain handling warnings — for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate cold-chain shipping and logistics to the destination market. When a buyer needs Aprotinin Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, artwork, line slot and cold-chain shipment plan delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the compounding and aseptic filling suites; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through API sourcing and bovine-source control, potency-bioassay and protein-characterisation development, related-protein and aggregate control, aseptic process design for a heat-labile protein, cold-chain and viral/TSE safety engineering, fill-volume and deliverable-dose accuracy, particulate and endotoxin control, container-closure integrity and shelf-life choices in real detail. For a biologic antifibrinolytic where potency assurance, protein integrity, viral/TSE safety and dose precision directly govern both efficacy and safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Aprotinin Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Aprotinin Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, validated water-for-injection systems, dedicated aseptic compounding and vial filling lines (aseptic-only for this heat-labile protein), validated sterility assurance, cold-chain handling, 100 % inspection and continuous environmental monitoring.
Which potencies and pack sizes of Aprotinin Injection do you supply?
Our standard presentation is the 10,000 KIU/mL solution of aprotinin in a vial, given by slow intravenous injection and infusion after a mandatory test dose. Custom potencies, fill configurations, vial formats, cold-chain-ready tamper-evident counts per pack and country-specific artwork are available under contract manufacturing agreements.
What is Aprotinin Injection mainly used for?
Aprotinin Injection is used to reduce perioperative blood loss and the need for blood transfusion in selected patients undergoing isolated coronary artery bypass graft surgery with cardiopulmonary bypass. It is a bovine-derived broad-spectrum serine protease inhibitor with antifibrinolytic activity; Farbe Firma verifies the potency bioassay, protein and related-protein profile, viral/TSE safety, pH, deliverable volume, particulate matter and endotoxin at release so each unit delivers a precise, reproducible dose. Because re-exposure can cause anaphylaxis, the product carries mandatory test-dose and antihistamine-prophylaxis labelling.
Can Farbe Firma support country-specific registrations for Aprotinin Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A and validated cold-chain stability packages, potency-bioassay and protein-characterisation method-validation data, bovine-source viral/TSE safety documentation, aseptic-sterility and container-closure reports, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations and tender qualification in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
What is the minimum order quantity for Aprotinin Injection contract manufacturing?
MOQs vary by potency, vial size, aseptic-process and cold-chain requirements, label complexity and dossier requirements. For our cardiac-surgery and critical-care biologic and small-volume parenteral presentations we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments